Risdiplam is the sole orally administered drug accepted with the treatment of SMA. It was FDA approved in 2020 for use in individuals two months of age and more mature, and it capabilities as an SMN2 gene splicing modifier leading to larger amounts of SMN protein. Oral administration is a https://penaiau752kpt5.dgbloggers.com/profile